# A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy Volunteers

> **NCT01248052** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 25 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** LY2979165
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01248052
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2011-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248052, "A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01248052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*